查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2088690

前列腺癌診斷市場：按產品類型、檢測類型、應用和最終用戶分類－2026-2032年全球市場預測

Prostate Cancer Diagnostics Market by Product Type, Test Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，攝護腺癌診斷市場規模將達到 135.2 億美元，複合年成長率為 8.92%。

主要市場統計數據
基準年 2025 74.3億美元
預計年份：2026年 80.7億美元
預測年份 2032 135.2億美元
複合年成長率 (%) 8.92%

前列腺癌的診斷正從間歇性的PSA檢測轉向風險適應性方法，該方法結合了前列腺​​特異性抗原（PSA）檢測、直腸指檢、多參數磁振造影（MRI）、標靶切片檢查、組織病理學和分子生物標記。這項轉變具有重要的臨床意義，因為攝護腺癌仍是全球男性最常見的癌症之一，根據GLOBOCAN 2022估計，全球整體每年新增病例約147萬例，死亡39.7萬例。

前列腺癌診斷的需求受到男性人口老化、早期檢測意識提高、泌尿系統醫療服務覆蓋範圍擴大以及在減少不必要切片檢查的同時識別具有臨床意義的疾病等因素的影響。關鍵產業趨勢包括前列腺癌診斷、PSA檢測、前列腺MRI、前列腺切片檢查、液態生物檢體、基因組檢測、人工智慧輔助病理學和精準腫瘤學。

診斷領域的變革性變化

多參數磁振造影（MRI）在切片檢查前的應用、MRI-超音波融合切片檢查的日益普及，以及比單獨使用PSA具有更高特異性的反射性生物標記檢測在臨床上的廣泛接受，正在改變我們診斷前列腺癌的方式。這些工具可幫助臨床醫生區分生長緩慢的腫瘤和具有臨床意義的前列腺癌，從而支持更合理地使用積極的後續觀察、手術、放射線治療和全身性治療。

人工智慧的累積影響

人工智慧正在診斷成像、病理學、工作流程優先排序和決策支援等領域創造累積價值。在前列腺磁振造影（MRI）領域，人工智慧工具正被開發用於輔助病灶檢測、PI-RADS評估、分割和報告一致性。在數位病理學領域，人工智慧可以輔助格里森評分、腫瘤定量、品管和工作量優先排序，尤其是在高通量檢查室中。

全球市場的關鍵區域洞察

由於美國及加拿大民眾對攝護腺癌篩檢的重視程度高，影像技術先進，健保報銷體系完善，且積極採用基因組檢測，北美仍是前列腺癌診斷領域的領先地區。歐洲受益於系統性的癌症防治計畫、基於指南的多參數磁振造影（MRI）應用，以及國家醫療體係日益重視早期診斷，儘管各國在醫療服務的可及性和報銷方面存在差異。在整個歐洲，完善的轉診途徑以及放射科和病理科之間的密切合作，為MRI主導的切片檢查策略的廣泛應用提供了支持。

經濟與政策集團主要群體分析

在東協地區，私人醫院的擴張、醫療旅遊中心的開發以及政府主導的癌症防治工作支撐了需求，但先進的前列腺磁振造影、融合切片檢查和基因組檢測等服務仍然集中在主要城市。在海灣合作理事會國家，透過公共投資、國家癌症策略、數位健康專案以及採購先進診斷平台，正在建立先進的腫瘤醫療體系，為高品質的前列腺癌診斷創造了有利環境。

主要國家前列腺癌診斷趨勢

美國是前列腺癌診斷領域創新和商業化的領先中心，這得益於其完善的泌尿系統網路、廣泛的影像資源、分子檢測能力以及積極的臨床試驗活動。加拿大強調以指南為基礎的醫療保健和公平的醫療服務獲取，而墨西哥和巴西則在大都會圈和醫療資源匱乏地區之間存在差距的情況下，仍在不斷擴展私營診斷和腫瘤治療體系。英國、德國、法國、義大利和西班牙正在推動以多參數磁振造影（MRI）為中心的診斷流程，其中德國和法國積極採用相關診斷技術，而英國則透過其國家健康計畫（NHS）強調癌症的早期診斷。

為行業領導者提供的實用建議

產業領導者應優先考慮經臨床驗證的解決方案，這些方案能夠減少不必要的切片檢查，提高具有臨床意義的前列腺癌的檢出率，並能無縫整合到泌尿系統、放射科和病理科的工作流程中。與大學附屬醫院、腫瘤專家、實驗室和公共衛生相關人員建立合作關係，可以加速實證檢驗的積累，並增強醫生的信心。

調查方法

本執行摘要基於二手研究，參考資料包括官方認可的公共衛生資訊來源、癌症流行病學資料庫、臨床指南、監管資訊、同行評審文獻以及診斷行業趨勢。主要參考領域包括全球癌症發生率報告、國家篩檢和診斷建議、影像學和病理學診斷標準、生物標記證據以及已發表的關於人工智慧輔助前列腺癌診斷的研究。

結論

前列腺癌診斷領域正朝著更精準和數據驅動的方向發展。雖然PSA檢測仍然至關重要，但其作用正日益受到多參數磁振造影、標靶切片檢查、生物標記、基因組分析、液態生物檢體研究、數位病理學以及人工智慧驅動的工作流程支援的補充。那些展現出臨床效用、能夠改善風險分層並融入實際診療路徑的技術，很可能獲得最廣泛的應用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 攝護腺癌診斷市場：依產品類型分類

  • 生物標記和試劑盒
    • 基因檢測套組
    • 分子診斷試劑盒
    • PSA檢測
  • 切片穿刺針
  • 影像系統
    • CT系統
    • 磁振造影系統
    • PET系統
    • 超音波診斷設備

第8章：前列腺癌診斷市場：依檢測類型分類

  • 切片檢查
  • 影像檢查
    • CT掃描
    • 核磁共振掃描
    • PET掃描
    • 超音波檢查
  • 分子檢測
    • NGS檢測
    • PCR檢測
  • PSA檢測

第9章：前列腺癌診斷市場：依應用分類

  • 基因檢測
  • 初步診斷
  • 監測和後續觀察

第10章 攝護腺癌診斷市場：依最終用戶分類

  • 門診手術中心
  • 診斷中心
  • 醫院和診所
  • 研究所

第11章 攝護腺癌診斷市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章 攝護腺癌診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 攝護腺癌診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • bioMerieux SA
  • DiaSorin SpA
  • F. Hoffmann-La Roche Ltd
  • Fujifilm Holdings Corporation
  • Fujirebio Holdings, Inc.
  • GE HealthCare Technologies Inc.
  • Genomic Health, Inc.
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Koninklijke Philips NV
  • Laboratory Corporation of America Holdings
  • MDxHealth SA
  • Myriad Genetics, Inc.
  • OPKO Health, Inc.
  • Proteomedix AG
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
  • Veracyte, Inc.
Product Code: MRR-A339DAEFAC09

The Prostate Cancer Diagnostics Market is projected to grow by USD 13.52 billion at a CAGR of 8.92% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.43 billion
Estimated Year [2026] USD 8.07 billion
Forecast Year [2032] USD 13.52 billion
CAGR (%) 8.92%

Prostate cancer diagnostics are moving from episodic PSA-driven testing toward risk-adapted pathways that combine prostate-specific antigen testing, digital rectal examination, multiparametric MRI, targeted biopsy, histopathology, and molecular biomarkers. This shift is clinically important because prostate cancer remains one of the most commonly diagnosed cancers in men worldwide, with GLOBOCAN 2022 estimating approximately 1.47 million new cases and nearly 397,000 deaths globally.

Demand for prostate cancer diagnostics is being shaped by aging male populations, higher awareness of early detection, expanded access to urology services, and the need to reduce unnecessary biopsies while identifying clinically significant disease. For industry visibility, the core themes include prostate cancer diagnostics, PSA testing, prostate MRI, prostate biopsy, liquid biopsy, genomic testing, AI pathology, and precision oncology.

Transformative Shifts in the Diagnostic Landscape

The diagnostic landscape is being transformed by the use of multiparametric MRI before biopsy, growing reliance on MRI-ultrasound fusion biopsy, and broader clinical acceptance of reflex biomarker tests that improve specificity beyond PSA alone. These tools help clinicians distinguish indolent tumors from clinically significant prostate cancer, supporting more appropriate use of active surveillance, surgery, radiotherapy, and systemic therapy.

Another major shift is the integration of molecular diagnostics and genomic classifiers into treatment planning. Tests that evaluate tumor biology, inherited risk, or actionable mutations are becoming more relevant as prostate cancer care aligns with precision medicine, especially for patients with high-risk, recurrent, or metastatic disease. Clinical guidelines increasingly support risk-based decision-making that incorporates PSA density, MRI findings, family history, pathology grade, and genomic information.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative value across imaging, pathology, workflow triage, and decision support. In prostate MRI, AI tools are being developed to assist lesion detection, PI-RADS assessment, segmentation, and reporting consistency. In digital pathology, AI can support Gleason grading, tumor quantification, quality control, and workload prioritization, particularly in high-volume laboratories.

The impact is strongest when AI is positioned as an assistive layer rather than a replacement for clinical judgment. Hospitals, imaging centers, and diagnostic laboratories are evaluating AI based on validation quality, interoperability, cybersecurity, regulatory clearance, and evidence that it improves sensitivity, specificity, turnaround time, or reader agreement in real-world practice. As datasets expand, AI-enabled prostate cancer diagnostics are expected to support more standardized interpretation across radiology and pathology environments.

Key Regional Insights Across Global Markets

North America remains a leading region for prostate cancer diagnostics because of high screening awareness, advanced imaging capacity, reimbursement pathways, and strong adoption of genomic tests in the United States and Canada. Europe benefits from structured cancer programs, guideline-driven use of multiparametric MRI, and national health systems that increasingly prioritize early diagnosis, although access and reimbursement vary across countries. Across the European region, organized referral pathways and strong radiology-pathology collaboration are supporting broader use of MRI-led biopsy strategies.

Asia-Pacific is expanding as China, India, Japan, South Korea, and Australia invest in oncology infrastructure, MRI capacity, pathology modernization, and private diagnostic networks. Latin America, led by Brazil and Mexico, shows rising demand for PSA testing, prostate biopsy, and imaging services but faces uneven access to advanced MRI and molecular testing. The Middle East, especially Gulf health systems, is investing in tertiary oncology centers, digital health infrastructure, and specialist training, while Africa remains constrained by specialist shortages, lower screening penetration, and limited access to MRI, biopsy, and pathology services outside major urban centers.

Key Group Insights Across Economic and Policy Blocs

Within ASEAN, demand is supported by expanding private hospitals, medical tourism hubs, and government cancer-control initiatives, though access to advanced prostate MRI, fusion biopsy, and genomic testing remains concentrated in larger cities. The GCC is building high-acuity oncology capacity through public investment, national cancer strategies, digital health programs, and procurement of advanced diagnostic platforms, creating a favorable environment for premium prostate cancer diagnostics.

The European Union is influential because of harmonized regulatory standards, strong clinical guideline adoption, and research funding for cancer diagnostics, including imaging, biomarkers, and digital pathology. BRICS economies combine large patient populations with rising healthcare investment, creating long-term opportunities for scalable PSA testing, imaging, pathology, and molecular diagnostics. G7 countries lead in adoption of advanced diagnostic workflows and precision oncology infrastructure, while NATO member markets overlap with many advanced Western health systems where digital pathology, AI validation, data protection, and cybersecurity are increasingly important procurement priorities.

Key Country Insights in Prostate Cancer Diagnostics

The United States is a major innovation and commercialization hub for prostate cancer diagnostics, supported by advanced urology networks, broad imaging access, molecular testing capabilities, and extensive clinical trial activity. Canada emphasizes guideline-based care and equitable access, while Mexico and Brazil are expanding private diagnostics and oncology capacity despite access gaps between metropolitan and underserved regions. The United Kingdom, Germany, France, Italy, and Spain are advancing multiparametric MRI-led diagnostic pathways, with Germany and France showing strong diagnostic technology adoption and the United Kingdom emphasizing earlier cancer diagnosis through national health programs.

Russia maintains demand through large urban oncology centers, although technology access can vary by region. China is scaling cancer diagnostics through hospital expansion, domestic medtech development, and rising awareness of men's health. India has substantial long-term growth potential due to demographics, expanding private-sector diagnostics, and increasing oncology investment, but affordability and specialist availability remain central. Japan, South Korea, and Australia are mature Asia-Pacific markets with strong imaging, pathology, and precision oncology capabilities, supporting adoption of prostate MRI, biomarker testing, targeted biopsy, and AI-enabled diagnostic workflows.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated solutions that reduce unnecessary biopsy, improve detection of clinically significant prostate cancer, and integrate smoothly into urology, radiology, and pathology workflows. Partnerships with academic medical centers, cancer hospitals, reference laboratories, and public health stakeholders can accelerate evidence generation and improve physician confidence.

Commercial teams should build region-specific market access strategies, including reimbursement dossiers, health-economic evidence, regulatory planning, and education for urologists, radiologists, pathologists, oncologists, and primary care physicians. Organizations should also invest in interoperability, cybersecurity, AI governance, and post-deployment performance monitoring to meet procurement requirements in hospitals, laboratories, and integrated delivery networks.

Research Methodology

This executive summary is grounded in secondary research from recognized public-health sources, cancer epidemiology databases, clinical guidelines, regulatory information, peer-reviewed literature, and diagnostic industry activity. Key reference domains include global cancer incidence reporting, national screening and diagnostic recommendations, imaging and pathology standards, biomarker evidence, and published studies on AI-assisted prostate cancer diagnostics.

The analysis applies triangulation across epidemiology, clinical adoption, reimbursement environment, technology maturity, regulatory readiness, and regional healthcare infrastructure. Insights were synthesized to identify durable market drivers, restraints, adoption patterns, and commercialization priorities without relying on unverified claims, market sizing, market share, or speculative forecasting.

Conclusion

The prostate cancer diagnostics landscape is entering a more precise, data-driven phase in which PSA testing remains foundational but is increasingly complemented by multiparametric MRI, targeted biopsy, biomarkers, genomic profiling, liquid biopsy research, digital pathology, and AI-enabled workflow support. The strongest adoption momentum will come from technologies that demonstrate clinical utility, improve risk stratification, and fit into real-world care pathways.

For industry participants, success will depend on evidence quality, reimbursement alignment, scalable deployment, regulatory compliance, and trust among clinicians. Organizations that combine robust science with accessible implementation models will be best positioned to address demand across mature and emerging healthcare systems while improving the early detection and management of clinically significant prostate cancer.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Prostate Cancer Diagnostics Market, by Product Type

  • 7.1. Biomarkers & Kits
    • 7.1.1. Genetic Testing Kits
    • 7.1.2. Molecular Diagnostic Kits
    • 7.1.3. Psa Tests
  • 7.2. Biopsy Needles
  • 7.3. Imaging Systems
    • 7.3.1. Ct Systems
    • 7.3.2. Mri Systems
    • 7.3.3. Pet Systems
    • 7.3.4. Ultrasound Systems

8. Prostate Cancer Diagnostics Market, by Test Type

  • 8.1. Biopsy
  • 8.2. Imaging Tests
    • 8.2.1. Ct Tests
    • 8.2.2. Mri Tests
    • 8.2.3. Pet Tests
    • 8.2.4. Ultrasound Tests
  • 8.3. Molecular Tests
    • 8.3.1. Ngs Tests
    • 8.3.2. Pcr Tests
  • 8.4. Psa Test

9. Prostate Cancer Diagnostics Market, by Application

  • 9.1. Genetic Testing
  • 9.2. Initial Diagnosis
  • 9.3. Monitoring & Follow-Up

10. Prostate Cancer Diagnostics Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Diagnostic Centers
  • 10.3. Hospitals & Clinics
  • 10.4. Research Laboratories

11. Prostate Cancer Diagnostics Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Prostate Cancer Diagnostics Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Prostate Cancer Diagnostics Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Concentration Analysis, 2025
    • 14.1.1. Concentration Ratio (CR)
    • 14.1.2. Herfindahl Hirschman Index (HHI)
  • 14.2. Recent Developments & Impact Analysis, 2025
  • 14.3. Product Portfolio Analysis, 2025
  • 14.4. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Abbott Laboratories
  • 15.2. Agilent Technologies, Inc.
  • 15.3. Beckman Coulter, Inc.
  • 15.4. Becton, Dickinson and Company
  • 15.5. bioMerieux S.A.
  • 15.6. DiaSorin S.p.A.
  • 15.7. F. Hoffmann-La Roche Ltd
  • 15.8. Fujifilm Holdings Corporation
  • 15.9. Fujirebio Holdings, Inc.
  • 15.10. GE HealthCare Technologies Inc.
  • 15.11. Genomic Health, Inc.
  • 15.12. Guardant Health, Inc.
  • 15.13. Illumina, Inc.
  • 15.14. Koninklijke Philips N.V.
  • 15.15. Laboratory Corporation of America Holdings
  • 15.16. MDxHealth SA
  • 15.17. Myriad Genetics, Inc.
  • 15.18. OPKO Health, Inc.
  • 15.19. Proteomedix AG
  • 15.20. QIAGEN N.V.
  • 15.21. Quest Diagnostics Incorporated
  • 15.22. Siemens Healthineers AG
  • 15.23. Sysmex Corporation
  • 15.24. Thermo Fisher Scientific Inc.
  • 15.25. Veracyte, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOMARKERS & KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOMARKERS & KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOMARKERS & KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENETIC TESTING KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENETIC TESTING KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENETIC TESTING KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MOLECULAR DIAGNOSTIC KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MOLECULAR DIAGNOSTIC KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MOLECULAR DIAGNOSTIC KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PSA TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PSA TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PSA TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOPSY NEEDLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMAGING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMAGING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMAGING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CT SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CT SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CT SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MRI SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MRI SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MRI SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PET SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PET SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PET SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ULTRASOUND SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ULTRASOUND SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ULTRASOUND SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMAGING TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IMAGING TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMAGING TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CT TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CT TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CT TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MRI TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MRI TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MRI TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PET TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PET TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PET TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ULTRASOUND TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ULTRASOUND TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ULTRASOUND TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MOLECULAR TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MOLECULAR TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MOLECULAR TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NGS TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NGS TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NGS TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PCR TESTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PCR TESTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PCR TESTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PSA TEST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PSA TEST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PSA TEST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENETIC TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GENETIC TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENETIC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INITIAL DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INITIAL DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INITIAL DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MONITORING & FOLLOW-UP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MONITORING & FOLLOW-UP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MONITORING & FOLLOW-UP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DIAGNOSTIC CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 153. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 155. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 156. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 158. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 159. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. GCC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 182. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 183. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 185. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 186. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. G7 PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 191. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 192. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 194. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 195. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. NATO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 210. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 211. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 213. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 214. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 217. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 219. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 220. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 222. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 223. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 226. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 228. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 229. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 231. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 232. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 244. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 246. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 247. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 249. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 250. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 251. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 255. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 256. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 258. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 259. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 260. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 264. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 265. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 267. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 268. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 271. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 273. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 274. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 276. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 277. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 278. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 279. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 280. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 282. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 283. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 285. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 286. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 287. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 297. INDIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 298. INDIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. INDIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 300. INDIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 301. INDIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. INDIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 303. INDIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 304. INDIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 305. INDIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 306. JAPAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 307. JAPAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 308. JAPAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 309. JAPAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 310. JAPAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. JAPAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 312. JAPAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 313. JAPAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 314. JAPAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 315. AUSTRALIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 316. AUSTRALIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. AUSTRALIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 318. AUSTRALIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 319. AUSTRALIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. AUSTRALIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 321. AUSTRALIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 322. AUSTRALIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 323. AUSTRALIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 324. SOUTH KOREA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 325. SOUTH KOREA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 326. SOUTH KOREA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKERS & KITS, 2018-2032 (USD MILLION)
  • TABLE 327. SOUTH KOREA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 328. SOUTH KOREA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. SOUTH KOREA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 330. SOUTH KOREA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, 2018-2032 (USD MILLION)
  • TABLE 331. SOUTH KOREA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 332. SOUTH KOREA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)